Amgen And Allergan File For US Rituximab
Submission Supported by Two Comparative Studies
Executive Summary
Amgen’s FDA submission for a biosimilar of Roche’s Rituxan rituximab brand comes shortly after Teva launched the first direct rival to the oncology drug in the US.
You may also be interested in...
Kanjinti and Mvasi Make ‘Solid Start’ In US
Launching its Kanjinti and Mvasi trastuzumab and bevacizumab biosimilars ‘at risk’ in July generated third-quarter sales of $81m for Amgen, contributing nearly half of global biosimilar turnover of $173m.
Pfizer Lines Up Trio Of US Biosimilar Launches
By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.
FDA Approves Pfizer's Ruxience Rituximab Biosimilar
Pfizer has received approval from the US Food and Drug Administration for the country’s second biosimilar rituximab, under the Ruxience label. However, the company has not yet revealed launch plans for the rival to Roche’s Rituxan brand.